Molnupiravir (Lagevrio, Merck Sharpe & Dohme) does not reduce frequency of hospital admissions or deaths in vaccinated, high-risk patients with COVID-19 in the community, according to latest results ...
People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...
In patients hospitalized with COVID-19, adding molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improved clinical outcomes, including 28-day mortality duration of hospital ...
The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...
RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the Phase 3 MOVe-NOW clinical trial to evaluate ...
Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...
SWEDESBORO, N.J.--(BUSINESS WIRE)--Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback